Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Mixed state Stories

2012-04-24 23:18:20

Possible changes in DSM-5 could do more harm than good for patients A Rhode Island Hospital psychiatrist and researcher explains the negative impact of broadening the diagnostic criteria for bipolar disorder in the upcoming Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). In a newly published commentary in the Journal of Clinical Psychiatry, Mark Zimmerman, M.D., explains that lowering the diagnostic threshold for bipolar disorder will likely do more harm than...

2011-10-24 14:34:00

WOODCLIFF LAKE, N.J., Oct. 24, 2011 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it began shipping the 5mg, 10mg, 15mg, and 20mg strengths of olanzapine orally disintegrating tablets, the generic version of Lilly's Zyprexa® Zydis®. According to IMS Health data, annual sales in the U.S. of Zyprexa® Zydis® are approximately $360 million. Important information about olanzapine ODT...

2011-09-05 11:15:19

How to diagnose and treat mood disorders in children and adolescents Recognition of bipolar disorder in adolescents is now clearly established. However, whether bipolarity exists in children remains controversial despite numerous studies that have been conducted on this topic in the last fifteen years. Since the diagnosis of bipolar disorder in children has been rising for the past ten years, clinicians, researchers, parents, and others who care for children are left wondering what...

2011-05-04 12:37:49

The evidence base for the prescribing of aripiprazole in maintenance treatment of bipolar disorder is limited to a single trial, sponsored by the manufacturer of aripiprazole, according to a rigorous appraisal of the evidence for its use led jointly by Alexander Tsai of Harvard University, Boston USA, and Nicholas Rosenlicht of the University of California San Francisco, USA. In the paper, published in this week's PLoS Medicine, the authors describe key limitations of the trial, which were...

2011-01-21 17:00:00

SILVER SPRING, Md., Jan. 21, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Viibryd tablets (vilazodone hydrochloride) to treat major depressive disorder in adults. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Major depressive disorder, also called major depression, is characterized by symptoms that interfere with a person's ability to work, sleep, study, eat, and enjoy once-pleasurable activities. Episodes of major depression often...

2010-04-30 08:00:00

WILMINGTON, Del., April 30 /PRNewswire/ -- Following last year's efforts to support bipolar depression awareness and education, AstraZeneca (NYSE: AZN) is relaunching The Bipolar Journey: Living With Bipolar Depression interactive exhibit in a second tour to patients and caregivers across America. The national 10-city tour will kick off at the Depression and Bipolar Support Alliance (DBSA) 2010 National Conference on April 29 in Itasca, Illinois. Those who have been touched by bipolar...

2010-04-30 06:00:00

WALTHAM, Mass., April 30 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that the United States Patent and Trademark Office has granted a Notice of Allowance of a patent covering the use of uridine in the treatment of patients with bipolar disorder. The patent, which upon issue will remain in force until 2025 prior to any patent term extensions, covers the use of an effective dose of a uridine composition to improve one or more of the symptoms of bipolar...

2009-12-04 15:30:00

INDIANAPOLIS, Dec. 4 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) today approved Zyprexa® (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17 years old. The updated Zyprexa label states that clinicians should take into consideration the increased potential for weight gain and hyperlipidemia in adolescents compared to adults and the...

2009-12-04 06:00:00

WILMINGTON, Del., Dec. 4 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tablets as adjunctive (add-on) treatment to antidepressants in adults with Major Depressive Disorder (MDD). SEROQUEL XR is the only medication in its class approved by the FDA to treat both major depressive disorder as adjunctive therapy and acute depressive...

2009-09-02 09:48:00

PHILADELPHIA, Sept. 2 /PRNewswire/ -- Pfizer, Inc. announced today it has agreed to plead guilty to criminal conduct and to pay more than $2 billion in criminal and civil fines, penalties and damages to settle allegations made in multiple whistleblower lawsuits that the pharmaceutical giant defrauded Medicare, Medicaid and other government-funded health care programs in connection with its market practices for four of its drugs. The settlement is the largest qui tam settlement in U.S....